Risk Factors of Subacute Thrombosis After Intracranial Stenting for Symptomatic Intracranial Arterial Stenosis

Stroke. 2017 Mar;48(3):784-786. doi: 10.1161/STROKEAHA.116.015538. Epub 2017 Jan 27.

Abstract

Background and purpose: We aimed to explore the risk factors of subacute thrombosis (SAT) after intracranial stenting for patients with symptomatic intracranial arterial stenosis.

Methods: From January to December 2013, all symptomatic intracranial arterial stenosis patients who underwent intracranial stenting in Beijing Tiantan Hospital were prospectively registered into this study. Baseline clinical features and operative data were compared in patients who developed SAT with those who did not. Binary logistic regression model was used to determine the risk factors associated with SAT.

Results: Of the 221 patients enrolled, 9 (4.1%) cases had SAT 2 to 8 days after stenting. Binary logistic analysis showed that SAT was related with tandem stenting (odds ratio [OR], 11.278; 95% confidence interval [CI], 2.422-52.519) and antiplatelet resistance (aspirin resistance: OR, 6.267; 95% CI, 1.574-24.952; clopidogrel resistance: OR, 15.526; 95% CI, 3.105-77.626; aspirin and clopidogrel resistance: OR, 12.246; 95% CI, 2.932-51.147; and aspirin or clopidogrel resistance: OR, 11.340; 95% CI, 2.282-56.344).

Conclusions: Tandem stenting and antiplatelet resistance might contribute to the development of SAT after intracranial stenting in patients with symptomatic intracranial arterial stenosis.

Keywords: aspirin; odds ratio; perfusion imaging; risk factors; thrombosis.

MeSH terms

  • Adult
  • Aged
  • Aspirin / therapeutic use
  • Clopidogrel
  • Constriction, Pathologic / therapy*
  • Female
  • Humans
  • Ischemic Attack, Transient
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use
  • Risk Factors
  • Stents / adverse effects*
  • Thrombosis / drug therapy*
  • Ticlopidine / analogs & derivatives
  • Ticlopidine / therapeutic use

Substances

  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • Ticlopidine
  • Aspirin